Steve Gavel Biography and Net Worth

Insider of Cabaletta Bio

Mr. Gavel joined Cabaletta in 2025 as Chief Commercial Officer. Prior to joining Cabaletta, from 2018 to 2025, Mr. Gavel was Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech reporting to the CEO, where he created and scaled its commercial organization and led implementation of all CAR T logistics and management of the leading CAR T centers in the U.S., in partnership with Johnson & Johnson, to successfully launch CARVYKTI, a treatment for patients with relapsed or refractory multiple myeloma. Earlier, Mr. Gavel led U.S. commercial strategy and development at Celgene (now Bristol Myers Squibb). Previously, he held commercial roles of increasing seniority at companies including Takeda Pharmaceuticals, Johnson & Johnson and Immunex. He holds a B.S. in Finance and Business Administration from Millersville University of Pennsylvania.

What is Steve Gavel's net worth?: The estimated net worth of Steve Gavel is at least $84.47 thousand as of January 21st, 2026. Gavel owns 22,170 shares of Cabaletta Bio stock worth more than $84,468 as of May 4th. This net worth evaluation does not reflect any other investments that Gavel may own. Learn More about Steve Gavel's net worth.
How do I contact Steve Gavel?: The corporate mailing address for Gavel and other Cabaletta Bio executives is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. Cabaletta Bio can also be reached via phone at 267-759-3100 and via email at [email protected]. Learn More on Steve Gavel's contact information.
Has Steve Gavel been buying or selling shares of Cabaletta Bio?: Steve Gavel has not been actively trading shares of Cabaletta Bio during the last quarter. Most recently, on Wednesday, January 21st, Steve Gavel bought 22,170 shares of Cabaletta Bio stock. The stock was acquired at an average cost of $2.27 per share, with a total value of $50,325.90. Following the completion of the transaction, the insider now directly owns 22,170 shares of the company's stock, valued at $50,325.90. Learn More on Steve Gavel's trading history.
Who are Cabaletta Bio's active insiders?: Cabaletta Bio's insider roster includes Gwendolyn Binder (Insider), Gwendolyn Binder (President, Science & Technology), David Chang (Chief Medical Officer), Steve Gavel (Insider), Michael Gerard (General Counsel), Steven Nichtberger (CEO), Mark Simon (Director), and Shawn Tomasello (Director). Learn More on Cabaletta Bio's active insiders.
Are insiders buying or selling shares of Cabaletta Bio?: In the last twelve months, Cabaletta Bio insiders bought shares 7 times. They purchased a total of 127,668 shares worth more than $286,210.51. The most recent insider tranaction occured on January, 21st when insider David J Chang bought 8,800 shares worth more than $19,888.00. Insiders at Cabaletta Bio own 11.3% of the company. Learn More about insider trades at Cabaletta Bio.
Information on this page was last updated on 1/21/2026.

Steve Gavel Insider Trading History at Cabaletta Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/21/2026	Buy	22,170	$2.27	$50,325.90	22,170

Steve Gavel Buying and Selling Activity at Cabaletta Bio

Cabaletta Bio Company Overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $4.01

$3.16

$4.00

50 Day Range

MA: $3.08

$2.47

$3.52

2 Week Range

Now: $4.01

$1.11

$4.00

Volume

22,299,369 shs

Average Volume

2,968,043 shs

Market Capitalization

$446.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.18